Skip to main content

Market Overview

Why Ardelyx Shares Tanked Today


Ardelyx (NASDAQ: ARDX) shares are trading lower after the company received an FDA letter regarding its NDA for tenapanor indicating deficiencies that preclude discussion of labeling and post-marketing requirements/comments at this time. 

Ardelyx Inc. is a biopharmaceutical company that develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.

At the time of publication, shares of Ardelyx were trading lower at $2.0150 per share. The stock has a 52-week low of $1.81 and a 52-week high of $9.23. 


Related Articles (ARDX)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Penny Stocks FDA Movers Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at